ANTARES PHARMA, INC. Insider Trading for June 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ANTARES PHARMA, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ANTARES PHARMA, INC. for June 2015.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.24 | 79,586 | 178,098 | 6,853,826 | 6.9 M to 6.9 M (-1.15 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.24 | 101,291 | 226,669 | 8,723,052 | 8.8 M to 8.7 M (-1.15 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.24 | 33,627 | 75,251 | 3,518,297 | 3.6 M to 3.5 M (-0.95 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 38,598 | 86,876 | 6,933,412 | 7 M to 6.9 M (-0.55 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 49,124 | 110,568 | 8,824,343 | 8.9 M to 8.8 M (-0.55 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 16,308 | 36,706 | 3,551,924 | 3.6 M to 3.6 M (-0.46 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 37,919 | 85,318 | 6,972,010 | 7 M to 7 M (-0.54 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 48,260 | 108,585 | 8,873,467 | 8.9 M to 8.9 M (-0.54 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 16,021 | 36,047 | 3,568,232 | 3.6 M to 3.6 M (-0.45 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 27,085 | 60,941 | 7,009,929 | 7 M to 7 M (-0.38 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 34,471 | 77,560 | 8,921,727 | 9 M to 8.9 M (-0.38 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.25 | 11,444 | 25,749 | 3,584,253 | 3.6 M to 3.6 M (-0.32 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.34 | 27,164 | 63,466 | 7,037,014 | 7.1 M to 7 M (-0.38 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.34 | 34,572 | 80,774 | 8,956,198 | 9 M to 9 M (-0.38 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.34 | 11,477 | 26,815 | 3,595,697 | 3.6 M to 3.6 M (-0.32 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.30 | 29,214 | 67,192 | 7,064,178 | 7.1 M to 7.1 M (-0.41 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.30 | 37,181 | 85,516 | 8,990,770 | 9 M to 9 M (-0.41 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.30 | 12,344 | 28,391 | 3,607,174 | 3.6 M to 3.6 M (-0.34 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.29 | 41,245 | 94,418 | 7,093,392 | 7.1 M to 7.1 M (-0.58 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.29 | 52,494 | 120,169 | 9,027,951 | 9.1 M to 9 M (-0.58 %) |
Jun 26 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.29 | 17,427 | 39,894 | 3,619,518 | 3.6 M to 3.6 M (-0.48 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.35 | 67,475 | 158,499 | 7,134,637 | 7.2 M to 7.1 M (-0.94 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.35 | 85,877 | 201,725 | 9,080,445 | 9.2 M to 9.1 M (-0.94 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.35 | 28,510 | 66,970 | 3,636,945 | 3.7 M to 3.6 M (-0.78 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 65,479 | 157,569 | 7,202,112 | 7.3 M to 7.2 M (-0.90 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 83,338 | 200,545 | 9,166,322 | 9.2 M to 9.2 M (-0.90 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 27,666 | 66,575 | 3,665,455 | 3.7 M to 3.7 M (-0.75 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 52,518 | 126,337 | 7,267,591 | 7.3 M to 7.3 M (-0.72 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 66,842 | 160,795 | 9,249,660 | 9.3 M to 9.2 M (-0.72 %) |
Jun 23 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 22,190 | 53,380 | 3,693,121 | 3.7 M to 3.7 M (-0.60 %) |
Jun 19 2015 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 1,447 | 3,589 | 7,320,109 | 7.3 M to 7.3 M (-0.02 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 1,842 | 4,568 | 9,316,502 | 9.3 M to 9.3 M (-0.02 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 611 | 1,515 | 3,715,311 | 3.7 M to 3.7 M (-0.02 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 76,728 | 189,948 | 7,321,556 | 7.4 M to 7.3 M (-1.04 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 97,654 | 241,752 | 9,318,344 | 9.4 M to 9.3 M (-1.04 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 32,419 | 80,256 | 3,715,922 | 3.7 M to 3.7 M (-0.86 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 19,889 | 47,839 | 7,398,284 | 7.4 M to 7.4 M (-0.27 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 25,313 | 60,885 | 9,415,998 | 9.4 M to 9.4 M (-0.27 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 8,403 | 20,212 | 3,748,341 | 3.8 M to 3.7 M (-0.22 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 43,506 | 104,506 | 7,418,173 | 7.5 M to 7.4 M (-0.58 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 55,372 | 133,009 | 9,441,311 | 9.5 M to 9.4 M (-0.58 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 18,382 | 44,155 | 3,756,744 | 3.8 M to 3.8 M (-0.49 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 35,915 | 86,322 | 7,461,679 | 7.5 M to 7.5 M (-0.48 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 45,710 | 109,864 | 9,496,683 | 9.5 M to 9.5 M (-0.48 %) |
Jun 18 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 15,175 | 36,473 | 3,775,126 | 3.8 M to 3.8 M (-0.40 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 22,973 | 55,144 | 3,790,301 | 3.8 M to 3.8 M (-0.60 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 5,267 | 12,641 | 3,813,274 | 3.8 M to 3.8 M (-0.14 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 1,568 | 3,771 | 3,818,541 | 3.8 M to 3.8 M (-0.04 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 54,370 | 130,510 | 7,497,594 | 7.6 M to 7.5 M (-0.72 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 69,198 | 166,103 | 9,542,393 | 9.6 M to 9.5 M (-0.72 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 12,467 | 29,921 | 7,551,964 | 7.6 M to 7.6 M (-0.16 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.40 | 15,866 | 38,078 | 9,611,591 | 9.6 M to 9.6 M (-0.16 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 3,710 | 8,923 | 7,564,431 | 7.6 M to 7.6 M (-0.05 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.41 | 4,722 | 11,356 | 9,627,457 | 9.6 M to 9.6 M (-0.05 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 44,010 | 106,874 | 7,568,141 | 7.6 M to 7.6 M (-0.58 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 56,012 | 136,020 | 9,632,179 | 9.7 M to 9.6 M (-0.58 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 18,551 | 44,986 | 7,612,151 | 7.6 M to 7.6 M (-0.24 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 23,611 | 57,257 | 9,688,191 | 9.7 M to 9.7 M (-0.24 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 18,551 | 44,986 | 7,630,702 | 7.6 M to 7.6 M (-0.24 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 23,611 | 57,257 | 9,711,802 | 9.7 M to 9.7 M (-0.24 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 18,595 | 45,156 | 3,820,109 | 3.8 M to 3.8 M (-0.48 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 7,838 | 19,007 | 3,838,704 | 3.8 M to 3.8 M (-0.20 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.43 | 7,838 | 19,007 | 3,846,542 | 3.9 M to 3.8 M (-0.20 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 67,627 | 166,782 | 7,649,253 | 7.7 M to 7.6 M (-0.88 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 86,071 | 212,268 | 9,735,413 | 9.8 M to 9.7 M (-0.88 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 58,251 | 144,445 | 7,716,880 | 7.8 M to 7.7 M (-0.75 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 74,137 | 183,838 | 9,821,484 | 9.9 M to 9.8 M (-0.75 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.47 | 28,574 | 70,469 | 3,854,380 | 3.9 M to 3.9 M (-0.74 %) |
Jun 15 2015 | ATRS | ANTARES PHARMA, IN ... | Flynn James E | 10% Owner | Sell | S | 2.48 | 24,612 | 61,030 | 3,882,954 | 3.9 M to 3.9 M (-0.63 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 2.18 | 198,789 | 433,360 | 198,789 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President & CEO | Option Exercise | A | 2.18 | 498,310 | 1,086,316 | 498,310 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | HOBBS EAMONN P | President & CEO | Grant | A | 0.00 | 245,532 | 0 | 445,254 | 199.7 K to 445.3 K (+122.94 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | GONELLA JACQUES | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Option Exercise | A | 2.18 | 193,241 | 421,265 | 193,241 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Fickenscher James E | Senior Vice Preside ... | Grant | A | 0.00 | 95,216 | 0 | 135,216 | 40 K to 135.2 K (+238.04 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Option Exercise | A | 2.18 | 288,786 | 629,553 | 288,786 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Grant | A | 0.00 | 142,294 | 0 | 457,164 | 314.9 K to 457.2 K (+45.19 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 2.18 | 3,389 | 7,388 | 314,870 | 318.3 K to 314.9 K (-1.06 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | Executive Vice Pres ... | Payment of Exercise | F | 2.10 | 3,526 | 7,405 | 318,259 | 321.8 K to 318.3 K (-1.10 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Option Exercise | A | 2.18 | 142,550 | 310,759 | 142,550 | |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Grant | A | 0.00 | 70,239 | 0 | 92,042 | 21.8 K to 92 K (+322.15 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | Stacey Jennifer Evans | SVP, General Counse ... | Payment of Exercise | F | 2.18 | 2,469 | 5,382 | 21,803 | 24.3 K to 21.8 K (-10.17 %) |
Jun 01 2015 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 2.18 | 99,395 | 216,681 | 99,395 |